[go: up one dir, main page]

LT4095130T - Žymėti prostatos specifinio membranos antigeno (psma) inhibitoriai, jų naudojimas kaip vizualizavimo medžiagų ir farmacinių medžiagų prostatos vėžiui gydyti - Google Patents

Žymėti prostatos specifinio membranos antigeno (psma) inhibitoriai, jų naudojimas kaip vizualizavimo medžiagų ir farmacinių medžiagų prostatos vėžiui gydyti

Info

Publication number
LT4095130T
LT4095130T LTEP22178736.9T LT22178736T LT4095130T LT 4095130 T LT4095130 T LT 4095130T LT 22178736 T LT22178736 T LT 22178736T LT 4095130 T LT4095130 T LT 4095130T
Authority
LT
Lithuania
Prior art keywords
psma
treatment
agents
specific membrane
membrane antigen
Prior art date
Application number
LTEP22178736.9T
Other languages
English (en)
Inventor
Matthias Eder
Klaus Kopka
Martin Schäfer
Ulrike Bauder-Wüst
Uwe Haberkorn
Martina Benesova
Walter Mier
Hans-Christian Kliem
Clemens KRATOCHWIL
Michael Eisenhut
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51903864&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LT4095130(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from EP20130004991 external-priority patent/EP2862857A1/en
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of LT4095130T publication Critical patent/LT4095130T/lt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0482—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group chelates from cyclic ligands, e.g. DOTA
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D295/145—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0402—Organic compounds carboxylic acid carriers, fatty acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • G01N33/575—
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/60—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances involving radioactive labelled substances

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nuclear Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
LTEP22178736.9T 2013-10-18 2014-10-17 Žymėti prostatos specifinio membranos antigeno (psma) inhibitoriai, jų naudojimas kaip vizualizavimo medžiagų ir farmacinių medžiagų prostatos vėžiui gydyti LT4095130T (lt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP20130004991 EP2862857A1 (en) 2013-10-18 2013-10-18 Labeled inhibitors of prostate specific membrane antigen (PSMA), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer
EP14175612 2014-07-03

Publications (1)

Publication Number Publication Date
LT4095130T true LT4095130T (lt) 2024-04-25

Family

ID=51903864

Family Applications (2)

Application Number Title Priority Date Filing Date
LTEP22178736.9T LT4095130T (lt) 2013-10-18 2014-10-17 Žymėti prostatos specifinio membranos antigeno (psma) inhibitoriai, jų naudojimas kaip vizualizavimo medžiagų ir farmacinių medžiagų prostatos vėžiui gydyti
LTPA2024522C LTPA2024522I1 (lt) 2013-10-18 2024-07-04

Family Applications After (1)

Application Number Title Priority Date Filing Date
LTPA2024522C LTPA2024522I1 (lt) 2013-10-18 2024-07-04

Country Status (34)

Country Link
US (11) US20160228587A1 (lt)
EP (6) EP3456700A1 (lt)
JP (7) JP2016535013A (lt)
KR (3) KR102282378B1 (lt)
CN (2) CN105636924B (lt)
AU (3) AU2014336638C1 (lt)
CA (1) CA2924360C (lt)
CL (1) CL2016000883A1 (lt)
CY (1) CY2024023I1 (lt)
DE (2) DE202014011593U1 (lt)
DK (1) DK4095130T3 (lt)
EA (1) EA037778B1 (lt)
ES (1) ES2977715T3 (lt)
FI (2) FI4095130T3 (lt)
FR (1) FR24C1028I2 (lt)
GE (8) GEAP202114132A (lt)
HR (1) HRP20240398T1 (lt)
HU (2) HUE066137T2 (lt)
IL (2) IL245113B (lt)
LT (2) LT4095130T (lt)
MX (3) MX2016005013A (lt)
MY (2) MY194484A (lt)
NL (1) NL301281I2 (lt)
NZ (1) NZ718812A (lt)
PE (2) PE20160678A1 (lt)
PH (2) PH12019502571A1 (lt)
PL (1) PL4095130T3 (lt)
RS (1) RS65324B1 (lt)
SA (1) SA516370842B1 (lt)
SG (1) SG11201602249RA (lt)
SI (1) SI4095130T1 (lt)
TN (1) TN2016000137A1 (lt)
WO (1) WO2015055318A1 (lt)
ZA (2) ZA201603380B (lt)

Families Citing this family (103)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2942065B1 (en) 2006-11-08 2018-06-27 Molecular Insight Pharmaceuticals, Inc. Heterodimers of glutamic acid
EP4464384A3 (en) 2007-08-17 2025-01-08 Purdue Research Foundation Psma binding ligand-linker conjugates and methods for using
US9951324B2 (en) 2010-02-25 2018-04-24 Purdue Research Foundation PSMA binding ligand-linker conjugates and methods for using
SG11201503303TA (en) 2012-11-15 2015-06-29 Endocyte Inc Conjugates for treating diseases caused by psma expressing cells
LT4095130T (lt) 2013-10-18 2024-04-25 Novartis Ag Žymėti prostatos specifinio membranos antigeno (psma) inhibitoriai, jų naudojimas kaip vizualizavimo medžiagų ir farmacinių medžiagų prostatos vėžiui gydyti
WO2015073678A1 (en) 2013-11-14 2015-05-21 Endocyte, Inc. Compounds for positron emission tomography
US10188759B2 (en) 2015-01-07 2019-01-29 Endocyte, Inc. Conjugates for imaging
WO2017029399A1 (en) * 2015-08-20 2017-02-23 Universität Zu Köln Pain tracking by pet-imaging (pain-trap)
PL3356385T3 (pl) * 2015-09-30 2021-06-28 Deutsches Krebsforschungszentrum Tagowane 18F inhibitory antygenu błonowego specyficznego dla gruczołu krokowego (PSMA) i ich zastosowanie jako środków do obrazowania w nowotworze gruczołu krokowego
US10688200B2 (en) * 2015-12-31 2020-06-23 Five Eleven Pharma Inc. Urea-based prostate specific membrane antigen (PSMA) inhibitors for imaging and therapy
LT3433238T (lt) * 2016-03-22 2021-09-27 The Johns Hopkins University Prostatai būdingi membraniniai antigenai tiksliniai aukšto giminingumo agentai, skirti prostatos vėžio endoradioterapijai
EP3474903B1 (en) 2016-06-23 2025-01-22 Cornell University Double targeted constructs to affect tumor kill
US10806806B2 (en) 2016-06-23 2020-10-20 Cornell University Trifunctional constructs with tunable pharmacokinetics useful in imaging and anti-tumor therapies
DE212016000299U1 (de) * 2016-12-15 2019-09-05 The European Atomic Energy Community (Euratom), Represented By The European Commission Behandlung vpm PMSA-exprimierenden Krebsarten
AU2018249559B2 (en) * 2017-04-05 2025-04-17 Cornell University Trifunctional constructs with tunable pharmacokinetics useful in imaging and anti-tumor therapies
US11491247B2 (en) 2017-05-02 2022-11-08 Cornell University Methods and reagents for tumor targeting with greater efficacy and less toxicity
US11191854B2 (en) 2017-05-05 2021-12-07 Centre For Probe Development And Commercialization Pharmacokinetic enhancements of bifunctional chelates and uses thereof
US10093741B1 (en) 2017-05-05 2018-10-09 Fusion Pharmaceuticals Inc. IGF-1R monoclonal antibodies and uses thereof
WO2018204872A2 (en) 2017-05-05 2018-11-08 Fusion Pharmaceuticals Inc. Igf-1r monoclonal antibodies and uses thereof
WO2018233798A1 (en) 2017-06-20 2018-12-27 ITM Isotopen Technologien München AG Novel psma-binding agents and uses thereof
CA3060143A1 (en) * 2017-05-24 2018-11-29 Itm Isotopen Technologien Munchen Ag Novel psma-binding agents and uses thereof
CN111032632B (zh) * 2017-05-30 2024-04-12 约翰霍普金斯大学 用于前列腺癌的腔内放射疗法的前列腺特异性膜抗原靶向的高亲和力剂
CN110678198B (zh) * 2017-06-09 2024-02-02 阿文塞勒欧洲有限公司 针对表达通用嵌合抗原受体的免疫细胞的靶向模块及其在治疗癌症、感染和自身免疫性病症中的用途
CN109510925A (zh) 2017-09-15 2019-03-22 南昌欧菲光电技术有限公司 摄像模组
CN109510921B (zh) 2017-09-15 2025-01-10 南昌欧菲光电技术有限公司 摄像模组
CN207184660U (zh) 2017-09-15 2018-04-03 南昌欧菲光电技术有限公司 摄像模组
US20200339625A1 (en) * 2017-10-22 2020-10-29 Provincial Health Services Authority Novel radiometal-binding compounds for diagnosis or treatment of prostate specific membrane antigen-expressing cancer
AU2018363807B2 (en) 2017-11-13 2024-11-28 Deutsches Krebsforschungszentrum A double-labeled probe for molecular imaging and use thereof
JP7324763B2 (ja) 2017-11-21 2023-08-10 ドイチェス クレブスフォルシュンクスツェントルム 分子イメージングのための二重標識プローブ及びその使用
FI4008359T3 (fi) * 2017-12-11 2024-11-11 Univ Muenchen Tech PSMA-ligandeja kuvantamista ja sisäistä sädehoitoa varten
WO2019115684A1 (en) * 2017-12-13 2019-06-20 Sciencons AS Complex comprising a psma-targeting compound linked to a lead or thorium radionuclide
AU2019217838C1 (en) * 2018-02-06 2024-05-02 Duke University PSMA targeted radiohalogenated urea-polyaminocarboxylates for cancer radiotherapy
MX380340B (es) 2018-03-14 2025-03-11 Instituto Nac De Investigaciones Nucleares 177lu-dota-hynic-ipsma como un radiofarmaco terapeutico dirigido al antigeno prostatico especifico de membrana.
DK3778592T3 (da) 2018-03-30 2023-06-19 Futurechem Co Ltd PSMA-målrettet radiolægemiddel til diagnosticering og behandling af prostatacancer
BR112020020961A2 (pt) * 2018-04-17 2021-01-19 Endocyte, Inc. Métodos de tratamento de câncer
JP7429688B2 (ja) * 2018-09-21 2024-02-08 エンドサイト・インコーポレイテッド シールド剤およびそれらの使用
JP2022501441A (ja) * 2018-09-21 2022-01-06 エンドサイト・インコーポレイテッドEndocyte, Inc. 癌を治療する方法
EP3856261A1 (en) * 2018-09-28 2021-08-04 Universität Heidelberg Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of psma-expressing cancers
DE102018126558A1 (de) 2018-10-24 2020-04-30 Helmholtz-Zentrum Dresden - Rossendorf E.V. Markierungsvorläufer mit Quadratsäure-Kopplung
WO2020108753A1 (en) 2018-11-28 2020-06-04 ITM Isotopen Technologien München AG Novel tumor antigen binding agents and uses thereof
AU2019407851B8 (en) 2018-12-18 2025-10-09 Provincial Health Services Authority Dual mode 18f-labelled theranostic compounds and uses thereof
KR102850587B1 (ko) * 2019-01-30 2025-08-27 테크니쉐 우니베르지테트 뮌헨 전립선 특이 막 항원 결합 이중 모드 방사선 추적자 및 치료법
EP3923998A1 (en) 2019-02-14 2021-12-22 Ruprecht-Karls-Universität Heidelberg Prostate specific membrane antigen (psma) ligands with improved tissue specificity
EP3923997A1 (en) 2019-02-14 2021-12-22 Deutsches Krebsforschungszentrum Prostate specific membrane antigen (psma) ligands comprising an amylase cleavable linker
US11396535B2 (en) 2019-03-01 2022-07-26 Provincial Health Services Authority Cyclic peptide analogs of melanocortin and amanitin and methods of making such
PL239934B1 (pl) 2019-04-12 2022-01-31 Narodowe Centrum Badan Jadrowych Osrodek Radioizotopow Polatom Pochodne inhibitorów PSMA do znakowania ⁹⁹ᵐTc poprzez HYNIC, zestaw radiofarmaceutyczny, preparat radiofarmaceutyczny oraz ich zastosowanie w diagnostyce raka prostaty
US12472272B2 (en) 2019-04-17 2025-11-18 Provincial Health Services Authority Radiolabelled compounds for diagnosis or treatment of prostate-specific membrane antigen- expressing cancer
AU2020262961B2 (en) * 2019-04-26 2025-10-23 Five Eleven Pharma Inc. Prostate-specific membrane antigen (PSMA) inhibitors as diagnostic and radionuclide therapeutic agents
EP3972627A4 (en) 2019-05-20 2023-06-21 Endocyte, Inc. Methods for preparing psma conjugates
KR20220024595A (ko) 2019-06-21 2022-03-03 프로빈셜 헬스 서비시즈 오쏘리티 전립선-특이적 막 항원을 표적으로 하는 방사성표지 화합물
EP3993837A1 (en) * 2019-07-02 2022-05-11 Advanced Accelerator Applications (Italy) Srl Prostate specific membrane antigen (psma) ligands and uses thereof
CA3148382A1 (en) 2019-07-25 2021-01-28 Bayer As Targeted radiopharmaceuticals for the diagnosis and treatment of prostate cancer
KR102269315B1 (ko) 2019-10-24 2021-06-24 서울대학교산학협력단 전립선 암의 영상 또는 치료를 위한 동위원소 표지 화합물
DE102019135564B4 (de) 2019-12-20 2022-05-19 Johannes-Gutenberg-Universität Mainz Verbindung für Smart-Drug-Delivery und pharmazeutisches Kit für duale nuklearmedizinisch-cytotoxische Theranostik
WO2021168028A1 (en) * 2020-02-18 2021-08-26 Endocyte, Inc. Method of treating psma-expressing cancers
CN113350531A (zh) * 2020-03-02 2021-09-07 上海核力星医药科技有限公司 前列腺特异性膜抗原结合配体偶联物及其应用
WO2021202376A1 (en) 2020-03-30 2021-10-07 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Method for blocking uptake of prostate-specific membrane antigen (psma)-targeted radionuclides by exocrine organs
JP2023524977A (ja) * 2020-05-06 2023-06-14 コーネル ユニヴァーシティー 銅含有セラグノスティック化合物及びその使用の方法
EP3919082A1 (en) * 2020-06-04 2021-12-08 Rigshospitalet Psma targeting urea-based ligands for prostate cancer radiotherapy and imaging
BR112023000763A2 (pt) 2020-07-13 2023-03-21 Point Biopharma Inc Composição farmacêutica, método para preparar 177lu-psma i&t, método para tratar um paciente, complexo, método para tratar um indivíduo
US11129912B1 (en) 2020-07-13 2021-09-28 POINT Biopharma Inc. Radiopharmaceutical and methods
CN112062695B (zh) * 2020-08-14 2021-04-06 北京大学第一医院 一种前列腺特异性膜抗原靶向抑制剂及应用和探针
WO2022043557A1 (en) 2020-08-31 2022-03-03 Advanced Accelerator Applications International Sa Method of treating psma-expressing cancers
EP4204020A1 (en) 2020-08-31 2023-07-05 Advanced Accelerator Applications International S.A. Method of treating psma-expressing cancers
CN112321673B (zh) * 2020-11-04 2022-09-20 北京市肿瘤防治研究所 一种前列腺特异性膜抗原靶向抑制剂及应用和探针
WO2022096103A1 (en) 2020-11-05 2022-05-12 ITM Isotopen Technologien München AG Combination of para-aminohippuric acid (pah) and radiolabeled complexes for treating cancer
WO2022106633A1 (en) * 2020-11-19 2022-05-27 Novartis Ag Synthesis of prostate specific membrane antigen (psma) ligands
WO2022111800A1 (en) 2020-11-25 2022-06-02 Itm Solucin Gmbh Stable formulations for radionuclide complexes
CN114685599A (zh) * 2020-12-30 2022-07-01 南京江原安迪科正电子研究发展有限公司 一种psma靶向抑制剂及放射性核素标记的psma靶向抑制剂、制备方法和用途
EP4023250A1 (en) * 2021-01-04 2022-07-06 Technische Universität München Dual mode radiotracer and -therapeutics
DE102021101216A1 (de) 2021-01-21 2022-07-21 Johannes Gutenberg-Universität Mainz, Körperschaft des öffentlichen Rechts Markierungsvorläufer und Radiotracer zur nuklearmedizinischen Diagnose und Therapie von Prostatakrebs induzierten Knochenmetastasen
CN112898270B (zh) * 2021-01-22 2023-03-21 周彤 一种诊疗一体的psma抑制剂、化合物及其制备方法与用途
CA3208778A1 (en) 2021-01-22 2022-07-28 Bayer Aktiengesellschaft Lrrc15 antibodies and conjugates thereof
CN112851637B (zh) * 2021-01-22 2022-11-18 北京瑞达福明科技有限公司 一种psma抑制剂、化合物及其制备方法与用途
WO2022167681A1 (en) 2021-02-08 2022-08-11 Stichting Radboud Universitair Medisch Centrum Psma-targeting ligands for multimodal applications
CA3212963A1 (en) 2021-04-23 2022-10-27 Reinier HERNANDEZ Psma-targeting ligands with optimal properties for imaging and therapy
AU2022276433A1 (en) * 2021-05-21 2023-12-07 Monopar Therapeutics Inc. Trivalent radioisotope bio-targeted radiopharmaceutical, methods of preparation and use
CN113372285B (zh) * 2021-05-28 2024-06-18 西南医科大学附属医院 前列腺特异性膜抗原抑制剂、其放射性核素标记物及制法和应用
DE102021114711B4 (de) 2021-06-08 2023-11-02 Medianezia GmbH Trislinker-konjugierte dimere Markierungsvorläufer und daraus abgeleitete Radiotracer
KR20240072996A (ko) 2021-07-30 2024-05-24 오사카 유니버시티 방사성 표지된 화합물 및 이의 용도
JP2024532475A (ja) * 2021-09-01 2024-09-05 天津恒瑞医薬有限公司 前立腺特異的膜抗原の阻害剤及びその医薬的使用
EP4400505A4 (en) 2021-09-03 2025-08-27 Bivision Pharmaceuticals Inc PEPTIDE-UREA DERIVATIVE, PHARMACEUTICAL COMPOSITION CONTAINING SAME AND ASSOCIATED APPLICATION
CN115806529A (zh) * 2021-09-15 2023-03-17 威智医药有限公司 Psma结合剂及其用途
CN114014843B (zh) * 2021-11-17 2022-09-20 北京大学第一医院 一种psma靶向核素/荧光双模态配体和分子探针与应用
US20250108139A1 (en) * 2022-01-30 2025-04-03 Bivision Pharmaceuticals, Inc Peptide urea derivative, pharmaceutical composition containing peptide urea derivative, and application of peptide urea derivative
WO2023208928A1 (en) 2022-04-26 2023-11-02 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Dosage of psma-ligands for fluorescence based detection of cancerous tissue
US20250303005A1 (en) 2022-05-17 2025-10-02 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Prostate specific membrane antigen (psma) ligands with improved renal clearance
AU2023270705A1 (en) 2022-05-17 2024-11-07 Albert-Ludwigs-Universität Freiburg Prostate specific membrane antigen (psma) ligands
KR20250016195A (ko) 2022-05-17 2025-02-03 도이체스크레브스포르슝스젠트룸스티프퉁데스외펜트리헨레크츠 전립선-특이적 막 항원(psma) 리간드
WO2023222679A1 (en) 2022-05-17 2023-11-23 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Prostate specific membrane antigen (psma) ligands
CN114874122A (zh) * 2022-05-31 2022-08-09 南京航空航天大学 一种新的小分子抑制剂及其制备方法和应用
CA3258344A1 (en) 2022-06-07 2023-12-14 Actinium Pharmaceuticals, Inc. CHELETARIANS AND BIFUNCTIONAL CONJUGATES
CN119343151A (zh) 2022-06-10 2025-01-21 北京大学 一种三功能化合物及其用途
EP4590345A2 (en) 2022-09-23 2025-07-30 Nuclidium AG High-purity copper radiopharmaceutical compositions and diagnostic and therapeutic uses thereof
TW202426433A (zh) 2022-09-23 2024-07-01 瑞士商紐利迪姆股份公司 成纖維細胞活化蛋白（ｆａｐ）抑制劑、ｆａｐ結合物及其診斷與治療用途
KR20250130683A (ko) 2023-01-10 2025-09-02 썬 파마 어드밴스트 리서치 컴패니 리미티드 리간드-약물 접합체
WO2025022285A2 (en) 2023-07-21 2025-01-30 Novartis Ag Psma-targeting radioligand treatment regimen
WO2025041103A1 (en) 2023-08-23 2025-02-27 Bright Peak Therapeutics Ag Psma targeting ligands and methods of use
WO2025071977A1 (en) * 2023-09-28 2025-04-03 The Johns Hopkins University Pet/ct atlas for segmentation
WO2025088147A1 (en) 2023-10-27 2025-05-01 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Theranostic psma-targeting ligands for the diagnosis and treatment of psma-expressing cancers and their solid phase synthesis
KR20250062978A (ko) * 2023-10-31 2025-05-08 서울대학교병원 신규한 전립선 특이적 막 항원 리간드 및 이의 용도
WO2025128807A1 (en) 2023-12-13 2025-06-19 Amgen Inc. Radiolabeled compounds for the detection of steap1
WO2025218879A1 (en) 2024-04-15 2025-10-23 Itm Technologies Munich Se Stable formulations comprising 225-actinium labeled complexes and methods for preparing the same

Family Cites Families (344)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4713249A (en) 1981-11-12 1987-12-15 Schroeder Ulf Crystallized carbohydrate matrix for biologically active substances, a process of preparing said matrix, and the use thereof
DE116208T1 (de) 1982-12-07 1985-02-28 Kyowa Hakko Kogyo Co., Ltd., Tokio/Tokyo Mitomycin-analoge.
JPS60255789A (ja) 1984-06-01 1985-12-17 Kyowa Hakko Kogyo Co Ltd マイトマイシン誘導体，その製造法および抗腫瘍剤
US5266333A (en) 1985-03-06 1993-11-30 American Cyanamid Company Water dispersible and water soluble carbohydrate polymer compositions for parenteral administration of growth hormone
DE3750846T2 (de) 1986-08-29 1995-05-11 Kyowa Hakko Kogyo Kk Mitomycin-derivate.
USH806H (en) 1987-07-16 1990-08-07 Fmc Corporation Herbicidal clomazone compositions and methods of use tolerant to corn and other crops
CA2044590A1 (en) 1989-11-13 1991-05-14 Marc D. Better Chimeric mouse-human a10 antibody with specificity to a human tumor cell antigen
US5627165A (en) 1990-06-13 1997-05-06 Drug Innovation & Design, Inc. Phosphorous prodrugs and therapeutic delivery systems using same
AU653565B2 (en) 1990-12-21 1994-10-06 Nikken Corporation Raw sewage disposal apparatus and prefab for accomodating the same
US6342491B1 (en) 1991-05-21 2002-01-29 American Home Products Corporation Method of treating estrogen receptor positive carcinoma with 17 α-dihydroequilin
US6291196B1 (en) 1992-01-31 2001-09-18 Research Corporation Technologies, Inc. Melanoma and prostate cancer specific antibodies for immunodetection and immunotherapy
US7070782B1 (en) 1992-11-05 2006-07-04 Sloan-Kettering Institute For Cancer Research Prostate-specific membrane antigen
US5674977A (en) 1993-02-05 1997-10-07 The Ontario Cancer Institute Branched synthetic peptide conjugate
GB9314623D0 (en) 1993-07-14 1993-08-25 Nordion Int Inc Localization and therapy with agents directed against prostate specific antigen in breast cancer
US6569432B1 (en) 1995-02-24 2003-05-27 Sloan-Kettering Institute For Cancer Research Prostate-specific membrane antigen and uses thereof
JP3538221B2 (ja) 1993-11-19 2004-06-14 富士写真フイルム株式会社 定着濃厚液およびそれを用いたハロゲン化銀写真感光材料の処理方法
US5417982A (en) 1994-02-17 1995-05-23 Modi; Pankaj Controlled release of drugs or hormones in biodegradable polymer microspheres
US5866679A (en) 1994-06-28 1999-02-02 Merck & Co., Inc. Peptides
GB9417873D0 (en) * 1994-09-06 1994-10-26 Sandoz Ltd Organic compounds
US6946133B1 (en) 1996-03-20 2005-09-20 The United States Of America As Represented By The Department Of Health And Human Services Prostate specific antigen oligo-epitope peptide
KR20060025233A (ko) 1996-04-01 2006-03-20 에픽스 메디칼, 인코포레이티드 생체활성화 진단용 영상 콘트라스트 제제
WO1997038313A1 (en) 1996-04-05 1997-10-16 The Johns Hopkins University A method of enriching rare cells
US5795877A (en) 1996-12-31 1998-08-18 Guilford Pharmaceuticals Inc. Inhibitors of NAALADase enzyme activity
US6054444A (en) 1997-04-24 2000-04-25 Guilford Pharmaceuticals Inc. Phosphonic acid derivatives
US5863536A (en) 1996-12-31 1999-01-26 Guilford Pharmaceuticals Inc. Phosphoramidate derivatives
US5672592A (en) 1996-06-17 1997-09-30 Guilford Pharmaceuticals Inc. Certain phosphonomethyl-pentanedioic acid derivatives thereof
US5902817A (en) 1997-04-09 1999-05-11 Guilford Pharmaceuticals Inc. Certain sulfoxide and sulfone derivatives
US5998362A (en) 1996-09-12 1999-12-07 Merck & Co., Inc. Conjugates useful in the treatment of prostate cancer
US6368598B1 (en) 1996-09-16 2002-04-09 Jcrt Radiation Oncology Support Services, Inc. Drug complex for treatment of metastatic prostate cancer
US5962521A (en) 1997-04-04 1999-10-05 Guilford Pharmaceuticals Inc. Hydroxamic acid derivatives
US6177404B1 (en) 1996-10-15 2001-01-23 Merck & Co., Inc. Conjugates useful in the treatment of benign prostatic hyperplasia
US5948750A (en) 1996-10-30 1999-09-07 Merck & Co., Inc. Conjugates useful in the treatment of prostate cancer
US6548260B1 (en) 1997-01-21 2003-04-15 Bayer Corporation Detection of PSA-α2-macroglobulin complex in a biological fluid
ES2402947T3 (es) 1997-04-10 2013-05-10 Stichting Katholieke Universiteit University Medical Centre Nijmegen PCA3, genes PCA3 y métodos de uso
WO1998052966A1 (en) 1997-05-19 1998-11-26 The Johns Hopkins University School Of Medecine Tissue specific prodrug
US6504014B1 (en) 1997-05-19 2003-01-07 The John Hopkins University Tissue specific prodrug
US6127333A (en) 1997-07-10 2000-10-03 Merck & Co., Inc. Conjugates useful in the treatment of prostate cancer
US6391305B1 (en) 1997-09-10 2002-05-21 Merck & Co., Inc. Conjugates useful in the treatment of prostate cancer
US20020115596A1 (en) 1997-10-27 2002-08-22 Merk & Co., Inc. Conjugates useful in the treatment of prostate cancer
TR200002260T2 (tr) 1997-12-02 2000-12-21 Merck & Co., Inc. Prostat kanserinin tedavisinde yararlı konjugatlar
ZA9810974B (en) 1997-12-02 1999-06-03 Merck & Co Inc Conjugates useful in the treatment of prostate cancer
US20040081659A1 (en) 1997-12-02 2004-04-29 Merck & Co., Inc. Conjugates useful in the treatment of prostate cancer
AU2896399A (en) 1998-03-03 1999-09-20 Exact Sciences Corporation Purification and detection processes using reversible affinity electrophoresis
US20020103136A1 (en) 1998-03-05 2002-08-01 Dong-Mei Feng Conjugates useful in the treatment of prostate cancer
US6232287B1 (en) 1998-03-13 2001-05-15 The Burnham Institute Molecules that home to various selected organs or tissues
US6093382A (en) 1998-05-16 2000-07-25 Bracco Research Usa Inc. Metal complexes derivatized with folate for use in diagnostic and therapeutic applications
FR2778820B1 (fr) 1998-05-20 2000-07-28 Rhone Poulenc Agrochimie Melanges herbicides a base d'aclonifen et de clomazone
ES2329851T3 (es) 1998-06-01 2009-12-01 Agensys, Inc. Nuevos antigenos transmembranables expresados en canceres humano y utilizacion de los mismos.
US6833438B1 (en) 1999-06-01 2004-12-21 Agensys, Inc. Serpentine transmembrane antigens expressed in human cancers and uses thereof
US6518033B1 (en) 1998-08-05 2003-02-11 The Research Foundation Of State University Of New York Method of detecting the presence of CD155 for diagnosis of cancer and to determine treatment
US20070020327A1 (en) 1998-11-10 2007-01-25 John Fikes Inducing cellular immune responses to prostate cancer antigens using peptide and nucleic acid compositions
US6174858B1 (en) 1998-11-17 2001-01-16 Merck & Co., Inc. Conjugates useful in the treatment of prostate cancer
US6602274B1 (en) 1999-01-15 2003-08-05 Light Sciences Corporation Targeted transcutaneous cancer therapy
US20030207808A1 (en) 1999-02-18 2003-11-06 Kinneret Savitzky Novel nucleic acid and amino acid sequences
WO2000059930A1 (en) 1999-04-05 2000-10-12 Merck & Co., Inc. A method of treating cancer
US6528499B1 (en) 2000-04-27 2003-03-04 Georgetown University Ligands for metabotropic glutamate receptors and inhibitors of NAALADase
WO2000064911A1 (en) 1999-04-28 2000-11-02 Georgetown University Ligands for metabotropic glutamate receptors
AUPQ014799A0 (en) 1999-05-04 1999-05-27 Access Pharmaceuticals Australia Pty Limited Amplification of folate-mediated targeting to tumor cells using polymers
US7166573B1 (en) 1999-05-28 2007-01-23 Ludwig Institute For Cancer Research Breast, gastric and prostate cancer associated antigens and uses therefor
US20040146516A1 (en) 1999-06-17 2004-07-29 Utah Ventures Ii L.P. Lumen-exposed molecules and methods for targeted delivery
MXPA02000560A (es) 1999-07-13 2003-10-14 Us Gov Health & Human Serv Proteina del marco de lectura alternativo del receptor y de celula t, (tarp) y usos de las mismas.
EP1246597B1 (en) 1999-08-03 2015-01-14 The Ohio State University Polypeptides and polynucleotides for enhancing immune reactivity to her-2 protein
US7361338B2 (en) 1999-10-05 2008-04-22 Agensys, Inc. Methods to inhibit growth of prostate cancer cells
US6692724B1 (en) 1999-10-25 2004-02-17 Board Of Regents, The University Of Texas System Ethylenedicysteine (EC)-drug conjugates, compositions and methods for tissue specific disease imaging
WO2001030804A2 (en) 1999-10-27 2001-05-03 Merck & Co., Inc. Salt form of a conjugate useful in the treatment of prostate cancer
US6428785B1 (en) 1999-10-28 2002-08-06 Immunolytics Inc. Method and composition for treating prostate cancer
US6511676B1 (en) 1999-11-05 2003-01-28 Teni Boulikas Therapy for human cancers using cisplatin and other drugs or genes encapsulated into liposomes
CA2391534A1 (en) 1999-11-15 2001-05-25 Drug Innovation & Design, Inc. Selective cellular targeting: multifunctional delivery vehicles
DZ3332A1 (fr) 2000-03-31 2001-10-11 Purdue Research Foundation Methode de traitement a l'aide de conjugues ligand-immunogene
US20030072794A1 (en) 2000-06-09 2003-04-17 Teni Boulikas Encapsulation of plasmid DNA (lipogenes™) and therapeutic agents with nuclear localization signal/fusogenic peptide conjugates into targeted liposome complexes
AU2002224401B2 (en) 2000-10-16 2007-12-06 Gilead Sciences, Inc. Nucleic acid ligands to the prostate specific membrane antigen
US20020132983A1 (en) 2000-11-30 2002-09-19 Junghans Richard P. Antibodies as chimeric effector cell receptors against tumor antigens
WO2002043773A2 (en) 2000-12-01 2002-06-06 The Johns Hopkins University Tissue specific prodrugs
JP2004536034A (ja) 2001-01-08 2004-12-02 ネオルクス コーポレイション 治療的および診断的化合物、組成物および方法
JP2005507857A (ja) 2001-02-07 2005-03-24 ベズ イズレイル ディーコネス メディカル センター 改変ｐｓｍａリガンド及びそれに関する利用
WO2002074345A2 (en) 2001-03-16 2002-09-26 Johns Hopkins University School Of Medicine Immune modulation by transduced hematopoietic stem cells expressing antigens and antigen-presenting cell regulatory molecules
PT1381611E (pt) 2001-03-21 2005-11-30 Molteni & C Analogos de ftalocianina substituidas com metal sem centro de simetria sua preparacao e uso em terapia fotodinamica e em diagnostico in vivo
CN1551760A (zh) 2001-03-29 2004-12-01 ҩ��Э�͹�˾ 用于治疗组织炎症和癌变的鸟苷酸环化酶受体拮抗剂
DE60231868D1 (de) 2001-04-24 2009-05-20 Purdue Research Foundation Folat-mimetika und deren folatrezeptorbindende konjugate
JP4868698B2 (ja) 2001-05-02 2012-02-01 パーデュー・リサーチ・ファウンデーション マクロファージが仲介する疾患の治療および診断
US20040092890A1 (en) 2001-05-10 2004-05-13 Ash Stephen R. Catheter lock solution including a photo-oxidant
US7109165B2 (en) 2001-05-18 2006-09-19 Sirna Therapeutics, Inc. Conjugates and compositions for cellular delivery
US7666414B2 (en) 2001-06-01 2010-02-23 Cornell Research Foundation, Inc. Methods for treating prostate cancer using modified antibodies to prostate-specific membrane antigen
US7514078B2 (en) 2001-06-01 2009-04-07 Cornell Research Foundation, Inc. Methods of treating prostate cancer with anti-prostate specific membrane antigen antibodies
IL158969A0 (en) 2001-06-01 2004-05-12 Cornell Res Foundation Inc Modified antibodies to prostate-specific membrane antigen and uses thereof
US20040018203A1 (en) 2001-06-08 2004-01-29 Ira Pastan Pegylation of linkers improves antitumor activity and reduces toxicity of immunoconjugates
EP1410022B1 (en) 2001-06-21 2009-05-06 GlycoMimetics, Inc. Detection and treatment of prostate cancer
US20030031677A1 (en) 2001-06-25 2003-02-13 Drug Innovation & Design, Incorporated Exponential pattern recognition based cellular targeting, compositions, methods and anticancer applications
WO2003004469A1 (en) 2001-07-02 2003-01-16 Dabur Research Foundation Anticancer activity of imino acid conjugates of methylglyoxal
US6596755B2 (en) 2001-07-02 2003-07-22 Dabur Research Foundation Oral formulation of methylglyoxal and its imino acid conjugates for human use
US7893223B2 (en) 2001-07-17 2011-02-22 Bracco Imaging S.P.A. Multidentate AZA ligands able to complex metal ions and the use thereof in diagnostics and therapy
WO2003018611A2 (en) 2001-08-24 2003-03-06 University Of Victoria Innovation And Development Corporation Proaerolysin containing protease activation sequences and methods of use for treatment of prostate cancer
US20030049203A1 (en) 2001-08-31 2003-03-13 Elmaleh David R. Targeted nucleic acid constructs and uses related thereto
CA2452288A1 (en) 2001-09-20 2003-03-27 Cornell Research Foundation, Inc. Methods and compositions for treating and preventing skin disorders using binding agents specific for psma
US20030232760A1 (en) 2001-09-21 2003-12-18 Merck & Co., Inc. Conjugates useful in the treatment of prostate cancer
DE60234782D1 (de) 2001-09-28 2010-01-28 Purdue Research Foundation Behandlungsverfahren mit liganden-immunogenkonjugaten
US20030215456A1 (en) 2001-10-02 2003-11-20 Sui-Long Yao Method of treating cancer
US20030133927A1 (en) 2001-10-10 2003-07-17 Defeo-Jones Deborah Conjugates useful in the treatment of prostate cancer
US20040058857A1 (en) 2001-11-29 2004-03-25 Siu-Long Yao Method of treating cancer
US20070031438A1 (en) 2001-12-10 2007-02-08 Junghans Richard P Antibodies as chimeric effector cell receptors against tumor antigens
AU2002364202A1 (en) 2001-12-21 2003-07-30 The Government Of The United States Of America, As Represented By The Secretary, Department Of Healt Novel metastasis suppressor gene on human chromosome 8
AU2003205077A1 (en) 2002-01-10 2003-07-30 Johns Hopkins University Imaging agents and methods of imaging naaladase of psma
US20060051380A1 (en) 2002-02-06 2006-03-09 The Johns Hopkins University Methods and compositions for the targeting of a systemic immune response to specific organs or tissues
US20040002587A1 (en) 2002-02-20 2004-01-01 Watkins Jeffry D. Fc region variants
US8491896B2 (en) 2002-06-14 2013-07-23 Immunomedics, Inc. Anti-pancreatic cancer antibodies
WO2003074450A2 (en) 2002-02-28 2003-09-12 The University Of Tennessee Research Corporation Radiolabeled selective androgen receptor modulators and their use in prostate cancer imaging and therapy
AU2003209447B8 (en) 2002-03-01 2008-10-23 Immunomedics, Inc. RS7 antibodies
US9770517B2 (en) 2002-03-01 2017-09-26 Immunomedics, Inc. Anti-Trop-2 antibody-drug conjugates and uses thereof
US20170281791A1 (en) 2002-03-01 2017-10-05 Immunomedics, Inc. Anti-trop-2 antibody-drug conjugates and uses thereof
US9745380B2 (en) 2002-03-01 2017-08-29 Immunomedics, Inc. RS7 antibodies
AU2003230615A1 (en) 2002-03-07 2003-09-22 The Johns Hopkins University Genomic screen for epigenetically silenced genes associated with cancer
US7534580B2 (en) 2002-05-01 2009-05-19 Ambrilia Biopharma Inc. PSP94 diagnostic reagents and assays
CA2484345C (en) 2002-05-06 2015-09-29 Endocyte, Inc. Folate-targeted imaging agents
AU2003243226A1 (en) 2002-05-15 2003-12-02 Endocyte, Inc. Vitamin-mitomycin conjugates
BR0311799A (pt) 2002-06-14 2005-05-10 Immunomedics Inc Anticorpo monoclonal hpam4
US7767803B2 (en) 2002-06-18 2010-08-03 Archemix Corp. Stabilized aptamers to PSMA and their use as prostate cancer therapeutics
AR040956A1 (es) 2002-07-31 2005-04-27 Schering Ag Nuevos conjugados de efectores, procedimientos para su preparacion y su uso farmaceutico
AU2003263964C1 (en) 2002-07-31 2010-08-19 Seagen Inc. Drug conjugates and their use for treating cancer, an autoimmune disease or an infectious disease
US7749968B2 (en) 2002-08-05 2010-07-06 The Johns Hopkins University Peptides for targeting the prostate specific membrane antigen
US7662795B2 (en) 2002-08-08 2010-02-16 The Johns Hopkins University Enhancement of adenoviral oncolytic activity by modification of the E1A gene product
US8487128B2 (en) 2002-11-26 2013-07-16 Chs Pharma, Inc. Protection of normal cells
CA2508831C (en) 2002-12-13 2012-05-01 Immunomedics, Inc. Immunoconjugates with an intracellularly-cleavable linkage
US8420086B2 (en) 2002-12-13 2013-04-16 Immunomedics, Inc. Camptothecin conjugates of anti-CD22 antibodies for treatment of B cell diseases
WO2004058158A2 (en) 2002-12-20 2004-07-15 The Johns Hopkins University Treatment of metastatic cancer with the b-subunit of shiga toxin
US7166691B2 (en) 2002-12-20 2007-01-23 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Saposin C and receptors as targets for treatment of benign and malignant disorders
US7226577B2 (en) 2003-01-13 2007-06-05 Bracco Imaging, S. P. A. Gastrin releasing peptide compounds
US20080008649A1 (en) * 2003-01-13 2008-01-10 Bracco Imaging S.P.A. Gastrin Releasing Peptide Compounds
WO2004069159A2 (en) 2003-01-27 2004-08-19 Endocyte, Inc. Vitamin receptor binding drug delivery conjugates
US7811564B2 (en) 2003-01-28 2010-10-12 Proscan Rx Pharma Prostate cancer diagnosis and treatment
EP1444990A1 (en) 2003-02-07 2004-08-11 Amersham plc Improved Radiometal Complex Compositions
US7160885B2 (en) 2003-02-10 2007-01-09 Cgi Pharmaceuticals, Inc. Certain 6, 8-(heteroaryl or aryl) disubstituted imidazo[1,2-a]pyrazines as modulators of Hsp90 complex activity
US7638122B2 (en) 2003-03-07 2009-12-29 University Of South Florida Stat3 antagonists and their use as vaccines against cancer
EP1603392A2 (en) 2003-03-07 2005-12-14 The University Of Toledo Paclitaxel hybrid derivatives
US20070179100A1 (en) 2003-04-09 2007-08-02 Muthiah Manoharan Protected monomers
DK1620544T3 (en) 2003-04-17 2019-01-14 Alnylam Pharmaceuticals Inc MODIFIED iRNA AGENTS
EP1641742A4 (en) 2003-05-01 2006-11-29 Nst Neurosurvival Technologies COMPOUNDS BINDING SELECTIVELY TO MEMBRANES OF APOPTOTIC CELLS
US8088387B2 (en) 2003-10-10 2012-01-03 Immunogen Inc. Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
US7172751B2 (en) 2003-06-13 2007-02-06 Immunomedics, Inc. D-amino acid peptides
US7232805B2 (en) 2003-09-10 2007-06-19 Inflabloc Pharmaceuticals, Inc. Cobalamin conjugates for anti-tumor therapy
US20050255042A1 (en) 2003-11-24 2005-11-17 The Regents Of The University Of California Office Of Technology Transfer, University Of California On-demand cleavable linkers for radioconjugates for cancer imaging and therapy
FR2864546A1 (fr) 2003-12-24 2005-07-01 Assist Publ Hopitaux De Paris Methode d'identification et de preparation de lymphocytes t regulateurs/suppresseurs, compositions et utilisations
WO2005070963A1 (en) 2004-01-12 2005-08-04 Applied Molecular Evolution, Inc Fc region variants
US8586932B2 (en) 2004-11-09 2013-11-19 Spectrum Dynamics Llc System and method for radioactive emission measurement
DE102004004787A1 (de) 2004-01-30 2005-08-18 Schering Ag Neue Effektor-Konjugate, Verfahren zu ihrer Herstellung und ihre pharmazeutische Verwendung
CA2556752C (en) 2004-02-23 2016-02-02 Genentech, Inc. Heterocyclic self-immolative linkers and conjugates
WO2005094882A1 (en) 2004-03-03 2005-10-13 Millennium Pharmaceuticals, Inc. Modified antibodies to prostate-specific membrane antigen and uses thereof
EP1723430A2 (fr) 2004-03-03 2006-11-22 Biomerieux Procede de detection de la forme libre activable du psa et son utilisation pour le diagnostic des pathologies benignes de la prostate et de l adenocarcinome de la prostate
ES2311895T3 (es) 2004-03-15 2009-02-16 F. Hoffmann-La Roche Ag El uso de los peptidos tipo bnp y de los peptidos tipo anf para evaluar el riesgo de padecer una complicacion cardio-vascular como frecuencia de sobrecarga del volumen.
US7910693B2 (en) 2004-04-19 2011-03-22 Proscan Rx Pharma Inc. Prostate cancer diagnosis and treatment
EP1737879B1 (en) 2004-04-19 2012-10-10 Archemix LLC Aptamer-mediated intracellular delivery of therapeutic oligonucleotides
NZ550934A (en) 2004-05-19 2010-05-28 Medarex Inc Chemical linkers and conjugates thereof
US7691962B2 (en) 2004-05-19 2010-04-06 Medarex, Inc. Chemical linkers and conjugates thereof
US20080008719A1 (en) 2004-07-10 2008-01-10 Bowdish Katherine S Methods and compositions for the treatment of prostate cancer
US8288557B2 (en) 2004-07-23 2012-10-16 Endocyte, Inc. Bivalent linkers and conjugates thereof
US20060148741A1 (en) 2004-07-26 2006-07-06 Government Of The Usa, Represented By The Secretary, Department Of Health And Human Services Metastasis suppressor gene on human chromosome 8 and its use in the diagnosis, prognosis and treatment of cancer
DK2213683T3 (da) 2004-08-04 2013-09-02 Mentrik Biotech Llc VARIANT-Fc-REGIONER
US20060045883A1 (en) 2004-08-26 2006-03-02 Jeffrey Molldrem Anti-cancer vaccines
WO2006024160A1 (en) 2004-08-30 2006-03-09 Neuromed Pharmaceuticals Ltd. Urea derivatives as calcium channel blockers
US8194660B2 (en) 2004-09-09 2012-06-05 Amx Llc System, method, and computer-readable medium for dynamic device discovery for servers binding to multiple masters
US7713944B2 (en) 2004-10-13 2010-05-11 Isis Pharmaceuticals, Inc. Oligomers comprising activated disulfides which bind to plasma proteins and their use for delivery to cells
WO2006049891A1 (en) 2004-10-27 2006-05-11 Janssen Pharmaceutica N.V. Trisubstituted thiophenes as progesterone receptor modulators
US8000773B2 (en) 2004-11-09 2011-08-16 Spectrum Dynamics Llc Radioimaging
EP1827505A4 (en) 2004-11-09 2017-07-12 Biosensors International Group, Ltd. Radioimaging
US20060140871A1 (en) 2004-11-30 2006-06-29 Sillerud Laurel O Magnetic resonance imaging of prostate cancer
US7741510B2 (en) 2005-01-13 2010-06-22 E. I. Du Pont De Nemours And Company Rheology control agents
EP1844351A4 (en) 2005-01-13 2017-07-05 Biosensors International Group, Ltd. Multi-dimensional image reconstruction and analysis for expert-system diagnosis
US20060155021A1 (en) 2005-01-13 2006-07-13 Lenges Christian P Coating compositions containing rheology control agents
CA2596469A1 (en) 2005-02-01 2006-08-10 Government Of The U.S.A, As Represented By The Secretary Department Of H Ealth & Human Services Biomarkers for tissue status
WO2006093991A1 (en) 2005-03-02 2006-09-08 The Cleveland Clinic Foundation Compounds which bind psma and uses thereof
JP2008536485A (ja) 2005-03-07 2008-09-11 アーケミックス コーポレイション Ｐｓｍａに対する安定化したアプタマーおよび前立腺癌治療薬としてのそれらの使用
US8088908B2 (en) 2005-05-10 2012-01-03 City Of Hope Humanized anti-prostate stem cell antigen monoclonal antibody
KR101068612B1 (ko) 2005-05-24 2011-09-30 휴마시스 주식회사 유사구조 단백질 비율 측정을 이용한 진단장치
DE602006020867D1 (de) 2005-06-14 2011-05-05 Protox Therapeutics Inc Verfahren zur behandlung oder prävention gutartiger prostatahyperplasie unter verwendung modifizierter porenbildender proteine
DK1912677T3 (da) 2005-06-20 2014-01-13 Psma Dev Company L L C PSMA-antistof-lægemiddel-konjugater
JP5175723B2 (ja) 2005-07-05 2013-04-03 パーデュー・リサーチ・ファウンデーション 単球介在性疾患を治療するための組成物の調製
US20070010014A1 (en) 2005-07-06 2007-01-11 General Electric Company Compositions and methods for enhanced delivery to target sites
US8644910B2 (en) 2005-07-19 2014-02-04 Biosensors International Group, Ltd. Imaging protocols
JP2009504783A (ja) 2005-08-19 2009-02-05 エンドサイト，インコーポレイテッド ビンカアルカロイド、類似体および誘導体のリガンド結合体
TW200811289A (en) 2005-08-19 2008-03-01 Cerus Corp Listeria-mediated immunorecruitment and activation, and methods of use thereof
EP2374480A3 (en) 2005-08-19 2013-05-01 Endocyte, Inc. Mutli-drug ligand conjugates
EP2015781A4 (en) 2005-09-12 2009-12-23 Univ Johns Hopkins COMPOSITIONS HAVING ANTIANGIOGENIC ACTIVITY AND USES THEREOF
US8926945B2 (en) 2005-10-07 2015-01-06 Guerbet Compounds comprising a biological target recognizing part, coupled to a signal part capable of complexing gallium
EP1957113A4 (en) 2005-11-21 2011-11-09 Medivas Llc POLYMER PARTICLES FOR THE OUTPUT OF MACROMOLECULES AND METHOD OF APPLICATION THEREFOR
EP3095467B1 (en) 2005-11-23 2020-05-06 Ventana Medical Systems, Inc. Antibody-enzyme conjugate
WO2007087131A2 (en) 2006-01-05 2007-08-02 The Johns Hopkins University Peptide prodrugs
WO2007081751A2 (en) 2006-01-05 2007-07-19 The Johns Hopkins University Compositions and methods for the treatment of cancer
US7635682B2 (en) 2006-01-06 2009-12-22 Genspera, Inc. Tumor activated prodrugs
US20070212337A1 (en) 2006-02-01 2007-09-13 The Johns Hopkins University Polypeptide-nucleic acid conjugate for immunoprophylaxis or immunotherapy for neoplastic or infectious disorders
ES2397973T3 (es) 2006-03-14 2013-03-12 Cancer Targeted Technology Llc Inhibidores peptidomiméticos del PSMA, compuestos que los comprenden y métodos de utilización
ATE509033T1 (de) 2006-03-20 2011-05-15 Univ California Manipulierte anti-prostatastammzellenantigen (psca)-antikörper für krebs-targeting
US20070225213A1 (en) 2006-03-23 2007-09-27 Kosak Matthew K Nucleic acid carriers for delivery of therapeutic agents
US20140314864A1 (en) 2006-03-31 2014-10-23 Massachusetts Institute Of Technology System for Targeted Delivery of Therapeutic Agents
ES2776100T3 (es) 2006-03-31 2020-07-29 Massachusetts Inst Technology Sistema para el suministro dirigido de agentes terapéuticos
US7842280B2 (en) 2006-09-06 2010-11-30 Case Western Reserve University Flexibly labeling peptides
CA2668197A1 (en) 2006-11-03 2008-05-15 Philip S. Low Ex vivo flow cytometry method and device
EP2942065B1 (en) 2006-11-08 2018-06-27 Molecular Insight Pharmaceuticals, Inc. Heterodimers of glutamic acid
WO2008079569A2 (en) 2006-11-21 2008-07-03 The Johns Hopkins University System and method for determining amount of radioactive material to administer to a patient
EP2500015A1 (en) 2006-12-05 2012-09-19 Landec Corporation Delivery of drugs
US8507434B2 (en) 2007-01-03 2013-08-13 The Johns Hopkins University Peptide modulators of angiogenesis and use thereof
CN101568352B (zh) 2007-01-11 2013-08-21 免疫医学股份有限公司 用于蛋白质、肽和其他分子的改进的f-18标记的方法和组合物
US20080214436A1 (en) 2007-01-26 2008-09-04 City Of Hope Methods and compositions for the treatment of cancer or other diseases
AU2008213702B2 (en) 2007-02-07 2014-04-24 Purdue Research Foundation Positron emission tomography imaging method
US20100104626A1 (en) 2007-02-16 2010-04-29 Endocyte, Inc. Methods and compositions for treating and diagnosing kidney disease
NZ599239A (en) 2007-03-14 2013-10-25 Endocyte Inc Binding ligand linked drug delivery conjugates of tubulysins
WO2008124197A1 (en) 2007-04-10 2008-10-16 The Johns Hopkins University Imaging and therapy of virus-associated tumors
EP2176293B1 (en) 2007-06-25 2019-04-03 Endocyte, Inc. Conjugates containing hydrophilic spacer linkers
CN104774175B (zh) 2007-06-26 2019-04-16 约翰·霍普金斯大学 标记的前列腺特异性膜抗原(psma)的抑制子、生物学评估及作为成像试剂的用途
GB0723246D0 (en) 2007-07-03 2008-01-09 Barton Michelle p53 modulator
WO2009029342A2 (en) 2007-07-13 2009-03-05 The Johns Hopkins University B7-dc variants
TR201000668T1 (tr) 2007-07-31 2010-06-21 The Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Neoplasti̇k veya enfeksi̇yoz bozukluklara yöneli̇k i̇mmunoprofi̇laksi̇ veya i̇mmünoterapi̇ i̇çi̇n poli̇pepti̇d-nüklei̇k asi̇t konjugati
WO2009021178A1 (en) 2007-08-08 2009-02-12 Chemimage Corporation Raman difference spectra based disease classification
EP4464384A3 (en) 2007-08-17 2025-01-08 Purdue Research Foundation Psma binding ligand-linker conjugates and methods for using
EP2185188B1 (en) 2007-08-22 2014-08-06 Medarex, L.L.C. Site-specific attachment of drugs or other agents to engineered antibodies with c-terminal extensions
US9585957B2 (en) 2007-09-07 2017-03-07 The Johns Hopkins University Adenosine receptor agonists and antagonists to modulate T cell responses
WO2009035942A1 (en) 2007-09-13 2009-03-19 Chemimage Corporation Distinguishing between renal oncocytoma and chromophobe renal cell carcinoma using raman molecular imaging
EP2644192B1 (en) 2007-09-28 2017-05-10 Pfizer Inc Cancer Cell Targeting Using Nanoparticles
AU2008316835B2 (en) 2007-10-25 2015-07-16 Endocyte, Inc. Tubulysins and processes for preparing
US8450290B2 (en) 2007-11-26 2013-05-28 Enzon Pharmaceuticals, Inc. Methods for treating androgen receptor dependent disorders including cancers
WO2009070302A1 (en) 2007-11-30 2009-06-04 The Johns Hopkins University Prostate specific membrane antigen (psma) targeted nanoparticles for therapy of prostate cancer
AU2008340354B2 (en) 2007-12-04 2014-04-17 Alnylam Pharmaceuticals, Inc. Folate-iRNA conjugates
WO2009076434A1 (en) 2007-12-12 2009-06-18 Molecular Insight Pharmaceuticals, Inc. Inhibitors of integrin vla-4
EP2823826A3 (en) 2008-01-09 2015-03-25 Molecular Insight Pharmaceuticals, Inc. Inhibitors of carbonic anhydrase IX
US8562945B2 (en) 2008-01-09 2013-10-22 Molecular Insight Pharmaceuticals, Inc. Technetium- and rhenium-bis(heteroaryl) complexes and methods of use thereof
US8565945B2 (en) 2008-01-17 2013-10-22 Lockheed Martin Corporation Method for managing vital train movements
EP2259836A2 (en) 2008-04-04 2010-12-15 Molecular Insight Pharmaceuticals, Inc. Radiolabeled treatment infusion system, apparatus, and methods of using the same
ITTO20080313A1 (it) 2008-04-22 2009-10-23 Marco Colombatti Anticorpo monoclonale isolato o suo frammento legante l'antigene specifico di membrana della prostata, suoi coniugati e suoi usi
EP2990487A1 (en) 2008-05-08 2016-03-02 Asuragen, INC. Compositions and methods related to mirna modulation of neovascularization or angiogenesis
US8852630B2 (en) 2008-05-13 2014-10-07 Yale University Chimeric small molecules for the recruitment of antibodies to cancer cells
PT2291659E (pt) 2008-05-13 2016-01-22 Univ Yale Moléculas quiméricas pequenas para o recrutamento de anticorpos contra células cancerosas
EP2309990B2 (en) 2008-06-16 2017-03-15 Pfizer Inc. Drug loaded polymeric nanoparticles and methods of making and using same
US20110305768A1 (en) 2008-07-01 2011-12-15 The Johns Hopkins University Quick-dissolving oral thin film for targeted delivery of therapeutic agents
LT3222615T (lt) 2008-08-01 2022-08-25 The Johns Hopkins University Psma surišantys agentai ir jų naudojimas
WO2010019446A1 (en) 2008-08-09 2010-02-18 University Of Iowa Research Foundation Nucleic acid aptamers
AU2009281732A1 (en) 2008-08-15 2010-02-18 Georgetown University Na channels, disease, and related assays and compositions
ES2438495T3 (es) 2008-09-08 2014-01-17 Psma Development Company, L.L.C. Compuestos para exterminar células cancerosas que expresan PSMA, resistentes a taxano
EP2166021A1 (en) 2008-09-16 2010-03-24 Ganymed Pharmaceuticals AG Monoclonal antibodies for treatment of cancer
PL2349274T3 (pl) 2008-09-17 2025-09-22 Endocyte, Inc. Koniugaty antyfolianów wiążące się z receptorem folianów
US20110288152A1 (en) 2008-10-17 2011-11-24 Purdue Research Foundation Psma binding ligand-linker conjugates and methods for using
AU2009322171A1 (en) 2008-12-05 2011-06-30 Molecular Insight Pharmaceuticals, Inc. CA-IX specific radiopharmaceuticals for the treatment and imaging of cancer
US8211402B2 (en) 2008-12-05 2012-07-03 Molecular Insight Pharmaceuticals, Inc. CA-IX specific radiopharmaceuticals for the treatment and imaging of cancer
EP3939617B1 (en) 2009-02-13 2024-11-13 Immunomedics, Inc. Intermediates for preparing conjugates with an intracellularly-cleavable linkage
EP2398504B1 (en) 2009-02-17 2018-11-28 Cornell Research Foundation, Inc. Methods and kits for diagnosis of cancer and prediction of therapeutic value
CA2754217A1 (en) 2009-03-02 2010-09-10 Massachusetts Institute Of Technology Methods and systems for treatment and/or diagnosis
EP2408465A4 (en) 2009-03-17 2012-11-28 Univ Johns Hopkins METHODS AND COMPOSITIONS FOR CANCER SCREENING
EP4420730A3 (en) * 2009-03-19 2024-11-13 The Johns Hopkins University Psma-targeting compounds and uses thereof
US10717750B2 (en) 2009-03-19 2020-07-21 The Johns Hopkins University 68Ga-labeled NOTA-chelated PSMA-targeted imaging and therapeutic agents
US9757084B2 (en) 2011-12-22 2017-09-12 The Johns Hopkins University Method and system for administering radiopharmaceutical therapy (RPT)
CN102714296A (zh) 2009-05-19 2012-10-03 Aic布莱博公司 复合集电器及形成其的方法
WO2010147965A2 (en) 2009-06-15 2010-12-23 Molecular Insight Pharmaceuticals, Inc. Process for production of heterodimers of glutamic acid
AU2010278734A1 (en) 2009-07-31 2012-02-23 Endocyte, Inc. Folate-targeted diagnostics and treatment
US8394922B2 (en) 2009-08-03 2013-03-12 Medarex, Inc. Antiproliferative compounds, conjugates thereof, methods therefor, and uses thereof
WO2011031517A1 (en) 2009-08-27 2011-03-17 Nuclea Biotechnologies, LLC Method and assay for determining fas expression
AU2010325969B2 (en) 2009-12-02 2016-10-20 Imaginab, Inc. J591 minibodies and cys-diabodies for targeting human prostate specific membrane antigen
DK2509634T3 (en) 2009-12-11 2019-04-23 Pfizer Stable formulations for lyophilization of therapeutic particles
AU2011212813B2 (en) 2010-02-04 2014-10-23 Radius Health, Inc. Selective androgen receptor modulators
US9951324B2 (en) 2010-02-25 2018-04-24 Purdue Research Foundation PSMA binding ligand-linker conjugates and methods for using
US20120322741A1 (en) 2010-02-25 2012-12-20 Purdue Research Foundation Psma binding ligand-linker conjugates and methods for using
US8685416B2 (en) 2010-03-02 2014-04-01 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Compositions and methods for the treatment of cancer
JP2010159277A (ja) 2010-03-04 2010-07-22 Sumitomo Chemical Co Ltd 有害生物防除組成物及び有害生物の防除方法
EP2371864A1 (en) 2010-03-23 2011-10-05 Ganymed Pharmaceuticals AG Monoclonal antibodies for treatment of cancer
WO2011127210A1 (en) 2010-04-06 2011-10-13 Massachusetts Institute Of Technology Targeted delivery of nucleic acids
EP2528625B1 (en) 2010-04-15 2013-07-10 Spirogen Sàrl Pyrrolobenzodiazepines and conjugates thereof
WO2011140340A1 (en) 2010-05-05 2011-11-10 Safety Syringes, Inc. Needle based helical coil safety device
CN101863924B (zh) 2010-05-17 2012-06-27 北京师范大学 99mTc标记肼基烟酰胺基-二氧辛酰-叶酸配合物及制备方法
JP2013531043A (ja) 2010-07-16 2013-08-01 ザ・ジョンズ・ホプキンス・ユニバーシティー 癌の免疫療法のための方法及び組成物
WO2012012710A2 (en) 2010-07-22 2012-01-26 The Johns Hopkins University Radiation sensitization agents for prostate cancer
US9580474B2 (en) 2010-09-08 2017-02-28 The Johns Hopkins University Polyionic papilloma virus-like particle (VLP) vaccines
KR101236142B1 (ko) 2010-09-30 2013-02-21 경북대학교 산학협력단 가돌리늄 착물을 함유하는 ｍｒｉ조영제
JP6275484B2 (ja) 2010-12-06 2018-02-07 モレキュラ インサイト ファーマシューティカルズ インコーポレイテッド Ｐｓｍａ標的化デンドリマー
WO2012135592A2 (en) 2011-03-31 2012-10-04 The Johns Hopkins University Theranostic imaging agents and methods of use
US9074000B2 (en) 2011-04-01 2015-07-07 Memorial Sloan Kettering Cancer Center T cell receptor-like antibodies specific for a WT1 peptide presented by HLA-A2
ES2541295T3 (es) 2011-04-21 2015-07-17 Orion Corporation Carboxamidas que modulan el receptor de andrógenos
US9180214B1 (en) 2011-04-22 2015-11-10 Stc.Unm Gonadotropin-releasing hormone receptor-targeting peptides and their use to treat and diagnose cancer
US9717484B2 (en) 2011-05-06 2017-08-01 The Johns Hopkins University Method and device for statistical tissue sampling using microdevices
WO2012166923A2 (en) 2011-05-31 2012-12-06 Bind Biosciences Drug loaded polymeric nanoparticles and methods of making and using same
WO2012174136A1 (en) * 2011-06-15 2012-12-20 Cancer Targeted Technology Llc Chelated psma inhibitors
TR201910084T4 (tr) * 2011-08-05 2019-08-21 Molecular Insight Pharm Inc Radyoaktif-etiketli prostat spesifik membran antijen inhibitörleri.
US10011632B2 (en) 2011-08-22 2018-07-03 Siemens Medical Solutions Usa, Inc. PSMA imaging agents
US9034318B2 (en) 2011-08-30 2015-05-19 The Regents Of The University Of Colorado, A Body Corporate Chemically modified cystathionine beta-synthase enzyme for treatment of homocystinuria
WO2013060793A1 (en) * 2011-10-25 2013-05-02 Technische Universität München Bifunctional ligands for radiometals
WO2013070457A2 (en) 2011-11-01 2013-05-16 The Johns Hopkins University Method and device for endoscopic abrasion
ES2729555T3 (es) 2011-11-30 2019-11-04 Univ Johns Hopkins Inhibidores homomultivalentes y heteromultivalentes de antígeno de membrana específico de próstata (PMSA) y usos de los mismos
AU2013207486A1 (en) 2012-01-06 2014-08-21 Molecular Insight Pharmaceuticals Metal complexes of poly(carboxyl)amine-containing ligands having an affinity for carbonic anhydrase IX
EP2822386B1 (en) 2012-02-29 2021-05-05 Purdue Research Foundation Folate receptor alpha binding ligands
US9498546B2 (en) 2012-03-14 2016-11-22 The Johns Hopkins University Synthesis and application of novel imaging agents conjugated to DPA 713 analogs for imaging inflammation
WO2013166110A1 (en) 2012-05-02 2013-11-07 Yale University Tlr-agonist-conjugated antibody recruiting molecules (tlr_arms)
KR20150022996A (ko) 2012-06-08 2015-03-04 아두로 바이오테크 암 면역요법을 위한 조성물 및 방법
DK2877599T3 (da) 2012-07-27 2020-01-20 Aragon Pharmaceuticals Inc Fremgangsmåder og sammensætninger til bestemmelse af resistens overfor androgenreceptorterapi
US20140107316A1 (en) 2012-10-16 2014-04-17 Endocyte, Inc. Drug delivery conjugates containing unnatural amino acids and methods for using
IN2015DN04147A (lt) 2012-10-16 2015-10-16 Endocyte Inc
US20140113322A1 (en) 2012-10-22 2014-04-24 The Johns Hopkins University Supramolecular nanobeacon imaging agents as protease sensors
WO2014066002A1 (en) 2012-10-23 2014-05-01 The Johns Hopkins University Novel self-assembling drug amphiphiles and methods for synthesis and use
SG11201503303TA (en) 2012-11-15 2015-06-29 Endocyte Inc Conjugates for treating diseases caused by psma expressing cells
US20140154702A1 (en) 2012-11-30 2014-06-05 Endocyte, Inc. Methods For Treating Cancer Using Combination Therapies
KR102002826B1 (ko) 2012-12-04 2019-07-23 삼성전자 주식회사 저장 장치, 플래시 메모리 및 저장 장치의 동작 방법
EA032986B1 (ru) 2012-12-21 2019-08-30 Медимьюн Лимитед Пирролобензодиазепины
EP2938364A1 (en) 2012-12-28 2015-11-04 Blend Therapeutics, Inc. Targeted conjugates encapsulated in particles and formulations thereof
ES2648096T3 (es) 2013-01-14 2017-12-28 Molecular Insight Pharmaceuticals, Inc. Radiofármacos a base de triazina y agentes de radioformación de imágenes
WO2014127365A1 (en) 2013-02-15 2014-08-21 Case Western Reserve University Psma ligands and uses thereof
US10207005B2 (en) 2013-02-15 2019-02-19 Case Western Reserve University Photodynamic therapy composition
US20140249315A1 (en) 2013-03-01 2014-09-04 Endocyte, Inc. Processes for preparing tubulysins
US9255262B2 (en) 2013-03-06 2016-02-09 Vision Global Holdings Ltd. Albumin-binding arginine deminase and the use thereof
US9567402B2 (en) 2013-03-14 2017-02-14 The Regents Of The University Of California Internalizing human monoclonal antibodies targeting prostate and other cancer cells
US10434194B2 (en) 2013-06-20 2019-10-08 Case Western Reserve University PSMA targeted nanobubbles for diagnostic and therapeutic applications
ES2865473T3 (es) 2013-07-10 2021-10-15 Sutro Biopharma Inc Anticuerpos que comprenden múltiples residuos de aminoácidos no naturales sitio-específicos, métodos para su preparación y métodos de uso
JP5817799B2 (ja) 2013-10-10 2015-11-18 ダイキン工業株式会社 空気調和機
EP3054983B1 (en) 2013-10-11 2019-03-20 Medimmune Limited Pyrrolobenzodiazepine-antibody conjugates
WO2015057692A1 (en) 2013-10-14 2015-04-23 The Johns Hopkins University Prostate-specific membrane antigen-targeted photosensitizers for photodynamic therapy
US10406246B2 (en) 2013-10-17 2019-09-10 Deutsches Kresbsforschungszentrum Double-labeled probe for molecular imaging and use thereof
US20150110716A1 (en) 2013-10-18 2015-04-23 Molecular Insight Pharmaceuticals, Inc. Methods of using spect/ct analysis for staging cancer
LT4095130T (lt) * 2013-10-18 2024-04-25 Novartis Ag Žymėti prostatos specifinio membranos antigeno (psma) inhibitoriai, jų naudojimas kaip vizualizavimo medžiagų ir farmacinių medžiagų prostatos vėžiui gydyti
WO2015057250A1 (en) 2013-10-18 2015-04-23 Psma Development Company, Llc Combination therapies with psma ligand conjugates
WO2015073678A1 (en) 2013-11-14 2015-05-21 Endocyte, Inc. Compounds for positron emission tomography
ITAN20130219A1 (it) 2013-11-21 2015-05-22 Gianluca Valentini Farmaco anti-cancro, comprendente un radioisotopo del rame
WO2015075477A1 (en) 2013-11-25 2015-05-28 Oxford Biotherapeutics Ltd Antibodies anti matriptase for the treatment of cancer
US9346846B1 (en) 2013-12-02 2016-05-24 Yale University Anti-cancer compounds and methods for treating cancer
US10363388B2 (en) 2013-12-18 2019-07-30 Koninklijke Philips N.V. System and method for enhancing sleep slow wave activity based on cardiac characteristics or respiratory characteristics
US11124845B2 (en) 2014-03-18 2021-09-21 The Johns Hopkins University PSMA-based molecular-genetic reporter system
CN106660943B (zh) 2014-05-06 2020-03-17 约翰霍普金斯大学 用于psma靶向的成像和放射疗法的金属/放射性金属标记的psma抑制物
EP2944635B1 (en) 2014-05-15 2018-11-28 Council of Scientific & Industrial Research Pyrazole linked benzimidazole conjugates and a process for preparation thereof
US9814759B2 (en) 2014-07-02 2017-11-14 Cheer Global Ltd. Pharmaceutical composition comprising recombinant hemoglobin protein or subunit-based therapeutic agent for cancer targeting treatment
LT3177632T (lt) 2014-08-06 2022-04-25 The Johns Hopkins University Prostatos specifinio membraninio antigeno (psma) inhibitoriaus provaistai
CA2961575C (en) 2014-08-06 2023-09-19 The Johns Hopkins University Methods for treating inflammatory bowel disease using prostate specific membrane antigen (psma) inhibitors
EP2993171A1 (en) 2014-09-04 2016-03-09 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Method for the production of 18F-labeled PSMA-specific PET-tracers
US10112974B2 (en) 2014-08-24 2018-10-30 Max-Planck-Gesellschaft Zur Foerderung Der Wissenschaften E.V. Method for the production of 18F-labeled active esters and their application exemplified by the preparation of a PSMA-specific PET-tracer
CA2959336A1 (en) 2014-08-25 2016-03-03 The Johns Hopkins University Methods and compositions related to prostate cancer therapeutics
AU2015315465B2 (en) 2014-09-08 2019-08-29 Molecular Insight Pharmaceuticals, Inc. Organ protection in PSMA-targeted radionuclide therapy of prostate cancer
EP3209336B1 (en) 2014-10-20 2019-12-11 Deutsches Krebsforschungszentrum 18f-tagged inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer
WO2016065142A2 (en) 2014-10-22 2016-04-28 The Johns Hopkins University New scaffolds and multifunctional intermediates for imaging psma and cancer therapy
WO2016081835A2 (en) 2014-11-21 2016-05-26 University Of Maryland, Baltimore Targeted structure-specific particulate delivery systems
KR101698654B1 (ko) 2014-12-24 2017-01-20 포항공과대학교 산학협력단 En2에 특이적으로 결합하는 dna 압타머 및 이의 용도
WO2016115445A1 (en) 2015-01-16 2016-07-21 The Johns Hopkins University Synthetic enhancement of the t-cell armamentarium as an anti-cancer therapy
US10596226B2 (en) 2015-01-16 2020-03-24 The Johns Hopkins University Albumin-proaerolysin prodrugs
UY36617A (es) 2015-04-13 2016-10-31 Aduro Biotech Inc Proteínas de fusión inmunogénicas para el tratamiento del cáncer
US11896614B2 (en) 2015-04-17 2024-02-13 Novartis Ag Methods for improving the efficacy and expansion of chimeric antigen receptor-expressing cells
US9808538B2 (en) 2015-09-09 2017-11-07 On Target Laboratories, LLC PSMA-targeted NIR dyes and their uses
KR101639599B1 (ko) 2015-11-09 2016-07-14 서울대학교산학협력단 펩타이드 싸이오우레아 유도체, 이를 포함하는 방사성 동위원소 표지 화합물 및 이를 유효 성분으로 함유하는 전립선암 치료 또는 진단용 약학적 조성물
FR3043970B1 (fr) 2015-11-25 2019-06-21 Medtech Sa Systeme mecanique de stabilisation au sol pour vehicules a roulettes
US10688200B2 (en) 2015-12-31 2020-06-23 Five Eleven Pharma Inc. Urea-based prostate specific membrane antigen (PSMA) inhibitors for imaging and therapy
EP3510399B1 (en) 2016-09-09 2023-03-01 On Target Laboratories, LLC Psma-targeted nir dyes and their uses
AU2018250609B2 (en) 2017-04-11 2024-05-09 Adarga, Llc Prodrugs of 2-PMPA for healthy tissue protection during PSMA-targeted cancer imaging or radiotherapy
WO2019115684A1 (en) 2017-12-13 2019-06-20 Sciencons AS Complex comprising a psma-targeting compound linked to a lead or thorium radionuclide
KR102902487B1 (ko) 2018-02-22 2025-12-18 더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 에반스 블루 유도체의 화학적 접합체 및 전립선 암 표적화를 위한 방사선 치료 및 조영제로서의 용도
KR20250156829A (ko) 2018-06-21 2025-11-03 리제너론 파아마슈티컬스, 인크. 이중특이적 항-psma x 항-cd28 항체 및 이의 용도

Also Published As

Publication number Publication date
GEP20217330B (en) 2021-12-10
CN105636924B (zh) 2018-08-07
KR20190016133A (ko) 2019-02-15
KR102282378B1 (ko) 2021-07-27
GEP20237496B (en) 2023-04-10
US20190060491A1 (en) 2019-02-28
PE20160678A1 (es) 2016-08-06
US20210283279A1 (en) 2021-09-16
CY2024023I2 (el) 2025-05-09
MX2021008977A (es) 2021-09-08
PH12016500656B1 (en) 2016-06-13
US20260007785A1 (en) 2026-01-08
FR24C1028I2 (fr) 2025-03-28
SG11201602249RA (en) 2016-05-30
AU2014336638B2 (en) 2017-10-19
CL2016000883A1 (es) 2016-10-21
US11931430B2 (en) 2024-03-19
EP4374924A2 (en) 2024-05-29
JP2024028742A (ja) 2024-03-05
EP3038996A1 (en) 2016-07-06
AU2018200419A1 (en) 2018-02-08
KR20210013350A (ko) 2021-02-03
CN109053616A (zh) 2018-12-21
EA201690495A1 (ru) 2016-10-31
RS65324B1 (sr) 2024-04-30
IL268974A (en) 2019-10-31
ZA201907607B (en) 2021-05-26
JP2018058847A (ja) 2018-04-12
DE202014011593U1 (de) 2023-08-23
PL4095130T3 (pl) 2024-06-10
US20190374660A1 (en) 2019-12-12
US10398791B2 (en) 2019-09-03
TN2016000137A1 (en) 2017-10-06
FI4095130T3 (fi) 2024-04-25
PH12019502571A1 (en) 2023-04-03
JP2019011368A (ja) 2019-01-24
JP7393485B2 (ja) 2023-12-06
GEP20237479B (en) 2023-03-27
US11951190B2 (en) 2024-04-09
IL268974B (en) 2020-08-31
US20240382631A1 (en) 2024-11-21
JP6556805B2 (ja) 2019-08-07
US20210177996A1 (en) 2021-06-17
AU2020201086B2 (en) 2021-07-08
AU2018200419B2 (en) 2019-11-14
FR24C1028I1 (fr) 2024-08-30
JP2019218351A (ja) 2019-12-26
GEAP202114132A (en) 2021-06-10
US11045564B2 (en) 2021-06-29
GEAP202215719A (en) 2022-12-26
SI4095130T1 (sl) 2024-05-31
EP4374924A3 (en) 2024-08-07
WO2015055318A1 (en) 2015-04-23
HUS2400024I1 (hu) 2024-08-28
JP2021059557A (ja) 2021-04-15
MX2021008976A (es) 2021-08-18
HUE066137T2 (hu) 2024-07-28
EP4095130B1 (en) 2024-01-31
US20160228587A1 (en) 2016-08-11
US10471160B2 (en) 2019-11-12
ZA201603380B (en) 2020-05-27
MX2016005013A (es) 2017-02-28
US20190008988A1 (en) 2019-01-10
EA037778B1 (ru) 2021-05-20
CY2024023I1 (el) 2025-05-09
JP7036774B2 (ja) 2022-03-15
CA2924360C (en) 2022-04-26
DE202014011600U1 (de) 2023-05-31
JP2016535013A (ja) 2016-11-10
CA2924360A1 (en) 2015-04-23
EP3415489A1 (en) 2018-12-19
US20240350680A1 (en) 2024-10-24
AU2014336638A1 (en) 2016-04-14
SA516370842B1 (ar) 2020-06-07
MY188934A (en) 2022-01-13
GEP20237497B (en) 2023-04-10
EP3495355A1 (en) 2019-06-12
CN105636924A (zh) 2016-06-01
IL245113B (en) 2020-08-31
GEAP202215720A (en) 2022-12-26
HRP20240398T1 (hr) 2024-06-07
JP2022159345A (ja) 2022-10-17
EP4095130A1 (en) 2022-11-30
CN109053616B (zh) 2022-08-19
MY194484A (en) 2022-11-30
US20260007784A1 (en) 2026-01-08
JP7194161B2 (ja) 2022-12-21
NL301281I2 (nl) 2024-08-01
US20190336622A1 (en) 2019-11-07
AU2020201086A1 (en) 2020-03-05
KR101947053B1 (ko) 2019-02-12
GEAP202215377A (en) 2022-11-10
FIC20240024I1 (fi) 2024-06-28
NZ718812A (en) 2017-08-25
EP3456700A1 (en) 2019-03-20
LTPA2024522I1 (lt) 2024-07-25
AU2014336638C1 (en) 2020-09-17
ES2977715T3 (es) 2024-08-29
IL245113A0 (en) 2016-06-30
PE20211760A1 (es) 2021-09-07
KR102210931B1 (ko) 2021-02-02
KR20160063398A (ko) 2016-06-03
PH12016500656A1 (en) 2016-06-13
DK4095130T3 (da) 2024-04-22
EP3038996B1 (en) 2022-06-15
HK1221711A1 (zh) 2017-06-09
JP6901451B2 (ja) 2021-07-14

Similar Documents

Publication Publication Date Title
HUS2400024I1 (hu) A prosztata-specifikus membrán antigén (PSMA) jelzett inhibitorai, alkalmazásuk képalkotásban és gyógyszerkészítmények prosztatarák kezelésére
CY1126819T1 (el) Σημασμενοι αναστολεις ειδικου προστατικου αντιγονου μεμβρανης (psma), η χρηση τους ως παραγοντες απεικονισης και φαρμακευτικοι παραγοντες για την αντιμετωπιση του καρκινου του προστατη
IL260342A (en) Urea-based prostate membrane-specific antigen suppressor for imaging and therapy
ZA201801024B (en) 18f-tagged inhibitors of prostate specific membrane antigen (psma) and their use as imaging agents for prostate cancer
PL2958945T3 (pl) Terapia skojarzona wykorzystująca przeciwciała przeciwko klaudynie 18.2 do leczenia nowotworu
PL3074035T3 (pl) Kompozycje zawierające przeciwciała anty-CEACAM1 i anty-PD do terapii raka
PL2956483T3 (pl) Cel terapeutyczny i diagnostyczny dla nowotworu, zawierający odczynniki wiążące dll3
HRP20220897T8 (hr) Kombinirana terapija koja uključuje antitijela protiv klaudina 18.2 za liječenje raka
SG2014008304A (en) C10rf32 antibodies, and uses thereof for treatment of cancer
IL240335B (en) Treatment of cancer using humanized anti-egfrviii chimeric antigen receptor
EP3033079A4 (en) Methods for the treatment of her2 amplified cancer
IL234989B (en) Compounds and compositions thereof for treating cancer
PT2976360T (pt) Terapia envolvendo anticorpos contra claudina 18.2 para o tratamento de cancro
EP3044197A4 (en) Halogenated compounds for cancer imaging and treatment and methods for their use
PT3089749T (pt) Preparações combinadas para o tratamento de cancro
PL2729008T3 (pl) Systemy, sposoby i formulacje do leczenia raka
PL3062790T3 (pl) Połączenia farmaceutyczne do leczenia raka
HRP20182041T1 (hr) Pripravci oksprenolola za liječenje raka
HUE047920T2 (hu) GD2-pozitív rák kezelésére szolgáló készítmények
SMT201700402T1 (it) Anticorpi anti-s-100a7 per il trattamento e la diagnosi del cancro
PT3356385T (pt) Inibidores etiquetados com 18f de antigénio de membrana específico de próstata (psma) e utilização dos mesmos como agentes de imagiologia para o cancro da próstata
AU2013904239A0 (en) Pharmaceutical combinations for the treatment of cancer